On January 14, 2026 GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, reported that the first patients have been enrolled in the Beginning Radiation Immediately with GammaTile at Glioblastoma Excision versus Standard of Care (BRIDGES) U.S. clinical trial for newly diagnosed glioblastoma (GBM). The BRIDGES trial is an innovative randomized study evaluating whether implanting GammaTile at the time of surgery can improve the survival outcomes for patients with newly diagnosed GBM.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Per Langoe, CEO of GT Medical Technologies, stated "GT Medical Technologies is proud to announce that the first patients have been enrolled in the BRIDGES trial, a groundbreaking study that will examine the ability of GammaTile to increase survivability for patients with newly diagnosed GBM. Patients who are newly diagnosed with GBM face an unacceptably poor prognosis, demonstrating a significant need for disruptive therapies that can improve the standard of care. With the recent completion of our ROADS trial for newly diagnosed brain metastases, we are very encouraged going into the BRIDGES trial."
The first BRIDGES patient enrollment was achieved at Westchester Medical Center in Valhalla, NY, by neurosurgeon Dr. Simon Hanft. "All of us at Westchester Medical Center are excited about giving our patients access to the BRIDGES trial and what it could mean for our patients suffering from GBM," stated Dr. Hanft. "We have utilized GammaTile successfully for a number of years, and we look forward to a significant contribution to the BRIDGES trial in an effort to lead the exploration of new advancements in care for patients with GBM."
Dr. Clark C. Chen, Professor and Director of the Brain Tumor Program, Brown University Health, Providence, RI, explained "Although glioblastoma remains a challenging disease, meaningful progress is underway. The BRIDGES trial exemplifies this momentum, offering patients access to the most advanced therapies available in modern neuro-oncology. At Brown Health, we are proud to make this trial available to our patients."
"GammaTile therapy is designed to be implanted at the time of GBM tumor resection, enabling radiation treatment to begin immediately rather than weeks after surgery," said Dr. Michael Garcia, Chief Medical Officer at GT Medical Technologies. "This represents a fundamental shift from the traditional care paradigm, where time between surgery and radiation allows for the tumor to start growing back. By delivering radiation from day one—when tumor burden is at its lowest—GammaTile offers a new way to rethink postoperative radiation. This approach underpins the promise of the BRIDGES trial and its potential to transform how GBM is treated."
(Press release, GT Medical Technologies, JAN 14, 2026, View Source [SID1234662049])